Denali Therapeutics (DNLI) Current Leases (2019 - 2025)
Historic Current Leases for Denali Therapeutics (DNLI) over the last 7 years, with Q3 2025 value amounting to $9.2 million.
- Denali Therapeutics' Current Leases rose 1403.68% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 1403.68%. This contributed to the annual value of $8.3 million for FY2024, which is 1443.53% up from last year.
- Denali Therapeutics' Current Leases amounted to $9.2 million in Q3 2025, which was up 1403.68% from $8.9 million recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Current Leases ranged from a high of $9.2 million in Q3 2025 and a low of $4.9 million during Q1 2021
- In the last 5 years, Denali Therapeutics' Current Leases had a median value of $7.1 million in 2022 and averaged $7.0 million.
- In the last 5 years, Denali Therapeutics' Current Leases surged by 3457.73% in 2022 and then plummeted by 79.26% in 2023.
- Denali Therapeutics' Current Leases (Quarter) stood at $5.5 million in 2021, then soared by 34.2% to $7.3 million in 2022, then dropped by 0.79% to $7.3 million in 2023, then grew by 14.44% to $8.3 million in 2024, then rose by 10.3% to $9.2 million in 2025.
- Its last three reported values are $9.2 million in Q3 2025, $8.9 million for Q2 2025, and $8.6 million during Q1 2025.